Gilead Sciences Given New $80.00 Price Target at Credit Suisse (GILD)
Equities research analysts at Credit Suisse hoisted their price target on shares of Gilead Sciences (NASDAQ:GILD) to $80.00 in a research note issued to investors on Wednesday, Stock Ratings Network.com reports. The firm currently has an “outperform” rating on the stock. Credit Suisse’s price objective would indicate a potential upside of 12.72% from the stock’s previous close.
Shares of Gilead Sciences (NASDAQ:GILD) traded down 0.29% on Wednesday, hitting $70.97. The stock had a trading volume of 9,399,040 shares. Gilead Sciences has a 52-week low of $32.07 and a 52-week high of $73.20. The stock has a 50-day moving average of $64.96 and a 200-day moving average of $58.17. The company has a market cap of $108.6 billion and a price-to-earnings ratio of 39.83. Gilead Sciences also was the target of unusually large options trading on Wednesday. Traders acquired 24,047 call options on the stock. This represents an increase of 109% compared to the average daily volume of 11,512 call options.
Gilead Sciences (NASDAQ:GILD) last released its earnings data on Tuesday, October 29th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.04. The company had revenue of $2.78 billion for the quarter, compared to the consensus estimate of $2.72 billion. During the same quarter in the previous year, the company posted $1.00 earnings per share. The company’s revenue for the quarter was up 14.7% on a year-over-year basis. On average, analysts predict that Gilead Sciences will post $1.99 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on GILD. Analysts at BMO Capital Markets set a $90.00 price target on shares of Gilead Sciences in a research note to investors on Wednesday. They now have an “outperform” rating on the stock. Separately, analysts at RBC Capital raised their price target on shares of Gilead Sciences from $72.00 to $80.00 in a research note to investors on Wednesday. They now have an “outperform” rating on the stock. Finally, analysts at Deutsche Bank reiterated a “buy” rating on shares of Gilead Sciences in a research note to investors on Friday, October 25th. They now have a $77.00 price target on the stock. Six research analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $71.70.
In other Gilead Sciences news, EVP Kevin Young sold 75,000 shares of the company’s stock in a transaction dated Wednesday, October 23rd. The shares were sold at an average price of $68.56, for a total value of $5,142,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.